A new drug, NXP800, shows promise in treating hormone therapy-resistant prostate cancer by targeting the Heat Shock Factor 1 (HSF1) pathway, which supports cancer cell growth.

The main finding of the observational study, published in the journal Neurology, suggests that alpha-blocker drugs used to treat urinary symptoms caused by an enlarged prostate gland may reduce ...

In the lab, the researchers found that NXP800 slowed the growth of prostate cancer cells—even for cells which were resistant to the hormone therapy enzalutamide. In biopsies of patients with ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

An innovative new drug being trialled to tackle certain cancers could also benefit patients with advanced prostate cancer whose treatment has stopped working, according to scientists. Experts ...

but their optimal use—such as which drug or drug combinations should be used first to achieve the best outcomes from prostate cancer treatment—is still being worked out. Nevertheless ...

CHICAGO, IL / ACCESS Newswire / January 22, 2025 / ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, ...

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive prostate cancer could unlock a sizeable new market for the drug.

Treatments of prostate cancer involved surgery, external beam therapy, hormone therapy, small molecular drug and cryosurgery [19-24]. Currently, natural plant extracts or human tissues active ...

Scientists are trialling an innovative new drug that could offer hope to patients with advanced prostate cancer, particularly those for whom current treatments have ceased to be effective. The ...